What should be the primary treatment in atrial fibrillation: Ventricular rate control or sinus rhythm control with long-term anticoagulation?

Journal of International Medical Research

Volumn 37, Issue 2, 2009, Pages 464-471

  Okcun, B ^a   Yigit, Z ^a   Yildiz, Ahmet ^b   Uzunhasan, I ^a   Orta, K ^a   Baskurt, M ^a   Kaya, A ^b   Kucukoglu, S ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b Department of Radiology   (Turkey)

Author keywords

Antigoagulants; Atrial firrillation; Imbolism; Mortality; Warfarin aspirin

Indexed keywords

ACETYLSALICYLIC ACID; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULATION; ARTICLE; CARDIOVERSION; CLINICAL TRIAL; CONSERVATIVE TREATMENT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEATH; DISEASE DURATION; EMBOLISM; FOLLOW UP; HEART ATRIUM FIBRILLATION; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MORTALITY; RANDOMIZED CONTROLLED TRIAL; SINUS RHYTHM; SINUS RHYTHM CONTROL; VENTRICULAR RATE CONTROL; AGED; DRUG EFFECT; FEMALE; HEART RATE; HEART VENTRICLE; MALE; PATHOPHYSIOLOGY; SINUS NODE; SURVIVAL; TIME; TREATMENT OUTCOME;

AGED; ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; EMBOLISM; FEMALE; HEART RATE; HEART VENTRICLES; HUMANS; MALE; SINOATRIAL NODE; SURVIVAL ANALYSIS; TIME FACTORS; TREATMENT OUTCOME; WARFARIN;

EID: 66649092721     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000903700222     Document Type: Article

References (20)

1. Pai SM, Pai RG: Management of atrial fibrillation. N Engl J Med 1992; 327: 1031 and 1031-1032.
2. Hennersdorf MG, Stauer BE: Atrial fibrillation. Internist (Berl) 2006; 47: 990-1000.
3. Fuster V, Rydén LE, Asinger RW, et al: ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. A Report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines and Policy Conferences (Committee to Develop Guidelines for the Management of Patients with Atrial Fibrillation): developed in Collaboration with the North American Society of Pacing and Electrophysiology. J Am Coll Cardiol 2001; 38: 1231-1266.
4. Wolf PA, Abbott RD, Kannel WB: Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983-988.
5. Prystowsky EN, Benson DW, Fuster V, et al: Management of patients with atrial fibrillation. A Statement for Healthcare Professionals. From the Subcommitte on Electrocardiography and Electrophysiology, American Heart Association. Circulation 1996; 93: 1262-1277.
6. Fuster V, Ryden LE, Cannom DS, et al: ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: full text: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guideline for the Management of Patients with Atrial Fibrillation) Developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Europace 2006; 8 651-745.
7. Sulke N, Sayers F, Lip GY: Rhythm control and cardioversion. Heart 2007; 93: 29-34.
8. Falk RH: Is rate control or rhythm control preferable in patients with atrial fibrillation? Rate control is preferable to rhythm control in the majority of patients with atrial fibrillation. Circulation 2005; 111: 3141-3150.
9. The AFFIRM Investigators: Baseline characteristics of patients with atrial fibrillation: the AFFIRM Study. Am Heart J 2002; 143: 991-1001.
10. Epstein AE, Vidaillet H, Greene HL, et al: Frequency of symtomatic atrial fibrillation in patients enrolled in the Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) study. J Cardiovasc Electrophysiol 2002; 13: 667-671.
11. Wyse DG, Waldo AL, DiMarco JP, et al: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
12. Coletta A, Thackray S, Nikitin N, et al: Clinical trials update: highlights of the scientific sessions of The American College of Cardiology 2002: LIFE, DANAMI 2, MADIT-2, MIRACLE-ICD, OVERTURE, OCTAVE, ENABLE 1 & 2, CHRISTMAS, AFFIRM, RACE, WIZARD, AZACS, REMATCH, BNP trial and HARDBALL. Eur J Heart Fail 2002; 4: 381-388.
13. Saxonhouse SJ, Curtis AB: Risks and benefits of rate control versus maintenance of sinus rhythm. Am J Cardiol 2003; 91: 27D-32D.
14. Khairy P, Nattel S: New insights into the mechanisms and management of atrial fibrillation. CMAJ 2002; 167: 1012-1020.
15. Louis A, Cleland JG, Crabbe S, et al: Clinical Trial Update: CAPRICORN, COPERNICUS, MIRACLE, STAF, RITZ-2, RECOVER and RENAISSANCE and cachexia and cholesterol in heart failure. Highlights of the Scientific Sessions of the American College of Cardiology, 2001. Eur J Heart Fail 2001; 3: 381-387.
16. Cheitlin MD, Armstrong WF, Aurigemma GP, et al: ACC/AHA/ASE 2003 Guideline Update for the Clinical Application of Echocardiography: summary article. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/ASE Committee to Update the 1997 Guidelines for the Clinical Application of Echocardiography). J Am Soc Echocardiogr 2003; 16: 1091-1110.
17. Ezekowitz MD, Netrebko PI: Anticoagulation in management of atrial fibrillation. Curr Opin Cardiol 2003; 18: 26-31.
18. Morley J, Marinchak R, Rials SJ, et al: Atrial fibrillation, anticoagulation, and stroke. Am J Cardiol 1996; 77: 38A-44A.
19. Cairns JA, Connolly SJ: Nonrheumatic atrial fibrillation. Risk of stroke and role of antithrombotic therapy. Circulation 1991; 84: 469-481.
20. Hohnloser SH, Kuck KH, Lilienthal J: Rhythm or rate control in atrial fibrillation - Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial. Lancet 2000; 356: 1789-1794.